Tricyclic heterocycles as anticancer agents

A compound of formula (I):

• wherein:
• T is a benzene ring or a five or six membered heteroaromatic ring;
• U is a benzene ring or a five or six membered heteroaromatic ring;
• with the proviso that at least one of T and U is a five or six membered heteroaromatic ring;
• X is selected from the group consisting of:
• —S—, —(CH2—CH2)—, and —CH═CH—;
• Y is selected from the group consisting of:
• A is a three to six membered aliphatic carbocycle or heterocycle attached at Y as a spiro ring, and A may be additionally substituted with one or two substituents chosen from OH, F, cyano, amino, (C1-C3)alkylamino, (C1-C3)dialkylamino, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, and (C1-C3)alkoxy;
• R1, R2, R3, and R4 are independently selected from the group consisting of:
• H, halo, —N3, —NR6R7, (C1-C6)alkyl, (C1-C6)haloalkyl, —OR6, —C(O)R6, —OC(O)R6, —C(O)NR6R7, —C(O)OR6, —SR6, —SO2R6, and —SO2NR6R7;
• R5 is —(CR15R16)p-Qq-(CR15R16)n-p-Z or
• R5a is ═CR14(CR15R16)p-Qq-(CR15R16)m-p-Z;
• Q is chosen from —O—, —NR14— and
• each R6 and R7 is independently selected from the group consisting of:
• H and (C1-C6)alkyl;
• R14 is H or (C1-C3)alkyl;
• R15 and R16, in each occurrence are chosen independently from H, OH, cyano, amino, (C1-C3)alkylamino, (C1-C3)dialkylamino, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, and (C1-C3)alkoxy, or, taken together, two of R14, R15 and R16 may form a three to seven membered heterocycle or non-aromatic carbocycle, wherein said three to seven membered carbocycle or heterocycle may be additionally substituted with one or two substituents chosen from OH, F, cyano, amino, (C1-C3)alkylamino, (C1-C3)dialkylamino, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, and (C1-C3)alkoxy;
• m is an integer from 1 to 3;
• n is an integer from 2 to 4;
• p is zero, 1 or 2;
• q is zero or 1;
• t is zero, 1 or 2;
• u is zero, 1 or 2, with the proviso that when Y is
• u is 2;
• v is 1, 2 or 3;
• with the proviso that when q is zero and R15 and R16, in all of their occurrences are H, n is not 4;
• Z is selected from the group consisting of:
• —NHSO2R17, —NHC(O)NR8R9, —NHC(O)OR8, —S(O)2NR8R9, substituted or unsubstituted cyclic carbamate;
• substituted or unsubstituted cyclic urea, cyclic imide and cyanoguanidine;
• R8 and R9 are independently selected from H, substituted or unsubstituted (C1-C6)alkyl, substituted or unsubstituted (C3-C7) cycloalkyl and substituted or unsubstituted (C5-C14)aryl;
• and
• R17 is chosen from phenyl and monocyclic heteroaryl, said phenyl and monocyclic heteroaryl optionally substituted with one or two substituents chosen from OH, halogen, cyano, nitro, (C1-C3)alkylamino, (C1-C3)dialkylamino, (C1-C3)acylamino, (C1-C3)alkylsulfonyl, (C1-C3)alkylthio, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, and (C1-C3)alkoxy.